Company logo

APLS - Apellis Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
Waltham, United States
Type: Equity

APLS price evolution
APLS
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $352.3 $453.5 $617.34 $766.36
Short term investments
Net receivables $206.44 $169.26 $110.91 $31.5
Inventory $146.36 $98.55 $103.22 $85.48
Total current assets $766.33 $796.77 $892.69 $954.25
Long term investments
Property, plant & equipment $21.09 $20.27 $22.07 $23.82
Goodwill & intangible assets
Total noncurrent assets $22.4 $21.45 $22.89 $24.61
Total investments
Total assets $788.73 $818.22 $915.58 $978.87
Current liabilities
Accounts payable $37.52 $18.19 $27.5 $31.49
Deferred revenue
Short long term debt $6.44 $5.74 $5.85 $5.83
Total current liabilities $247.59 $185.63 $174.84 $138.64
Long term debt $104.49 $103.84 $104.95 $106.04
Total noncurrent liabilities $346.62 $400.31 $395.34 $428.1
Total debt $110.93 $109.58 $110.8 $111.87
Total liabilities $594.21 $585.95 $570.17 $566.75
Shareholders' equity
Retained earnings -$2837.49 -$2748.91 -$2608.68 -$2486.64
Other shareholder equity -$3.54 -$1.06 -$0.8 -$0.78
Total shareholder equity $194.52 $232.27 $345.4 $412.12
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $352.3 $553.07 $641.75 $567.04
Short term investments $60.36 $311.87
Net receivables $206.44 $29.17 $10.1
Inventory $146.36 $85.71 $16.29
Total current assets $766.33 $719.52 $824.05 $917.19
Long term investments
Property, plant & equipment $21.09 $24.89 $26.08 $24.52
Goodwill & intangible assets
Total noncurrent assets $22.4 $40.69 $57.72 $43.38
Total investments $60.36 $311.87
Total assets $788.73 $760.22 $881.76 $960.57
Current liabilities
Accounts payable $37.52 $37.34 $16.91 $8.48
Deferred revenue
Short long term debt $6.44 $5.63 $4.12 $3.69
Total current liabilities $247.59 $167.61 $131.85 $128.33
Long term debt $104.49 $408.38 $206.1 $374.05
Total noncurrent liabilities $346.62 $422.74 $551.26 $627.68
Total debt $110.93 $112.71 $210.22 $377.73
Total liabilities $594.21 $590.35 $683.1 $756.01
Shareholders' equity
Retained earnings -$2837.49 -$2308.86 -$1656.69 -$926.35
Other shareholder equity -$3.54 -$2.52 -$2.09 -$0.12
Total shareholder equity $194.52 $169.87 $198.66 $204.56
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $146.38 $110.4 $94.97 $44.85
Cost of revenue $19.91 $22.41 $8.38 $7.81
Gross Profit $126.47 $87.99 $86.59 $37.04
Operating activities
Research & development $69.28 $79.42 $95.66 $110.03
Selling, general & administrative $141.7 $145.65 $111.37 $102.09
Total operating expenses $210.98 $225.07 $207.03 $212.12
Operating income -$84.52 -$137.08 -$120.44 -$175.08
Income from continuing operations
EBIT -$79.75 -$132.69 -$114.5 -$169.97
Income tax expense $1.42 $0.23 $0.19 $0.28
Interest expense $7.4 $7.31 $7.34 $7.53
Net income
Net income -$88.58 -$140.24 -$122.04 -$177.78
Income (for common shares) -$88.58 -$140.24 -$122.04 -$177.78
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $396.59 $75.42 $66.56 $250.65
Cost of revenue $58.51 $5.64 $0.2
Gross Profit $338.08 $69.79 $66.36 $250.65
Operating activities
Research & development $354.39 $387.24 $345.87 $299.92
Selling, general & administrative $500.81 $277.16 $176.77 $139.4
Total operating expenses $855.2 $664.4 $602.64 $464.37
Operating income -$517.12 -$594.61 -$536.28 -$213.73
Income from continuing operations
EBIT -$496.92 -$618.88 -$732.76 -$313.09
Income tax expense $2.13 $0.67 $0.35 $1.84
Interest expense $29.58 $32.63 $13.24 $29.94
Net income
Net income -$528.63 -$652.17 -$746.35 -$344.87
Income (for common shares) -$528.63 -$652.17 -$746.35 -$344.87
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$88.58 -$140.24 -$122.04 -$177.78
Operating activities
Depreciation $0.49 $0.41 $0.41 $0.4
Business acquisitions & disposals
Stock-based compensation $26.22 $21.63 $29.28 $28.82
Total cash flows from operations -$97.88 -$169.09 -$150.16 -$177.62
Investing activities
Capital expenditures $0 -$0.05 -$0.37 -$0.26
Investments
Total cash flows from investing $0 -$0.05 -$0.37 -$0.26
Financing activities
Dividends paid
Sale and purchase of stock $27.09 $5.76 $26.09 $402.11
Net borrowings
Total cash flows from financing -$3.91 $5.75 $1.56 $391.11
Effect of exchange rate $0.58 -$0.46 -$0.05 $0.06
Change in cash and equivalents -$101.2 -$163.84 -$149.01 $213.28
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$528.63 -$652.17 -$746.35 -$344.87
Operating activities
Depreciation $1.7 $1.49 $1.49 $0.86
Business acquisitions & disposals
Stock-based compensation $105.94 $91.08 $70.67 $45.38
Total cash flows from operations -$594.74 -$513.75 -$563.13 -$160.49
Investing activities
Capital expenditures -$0.67 -$1.52 -$1.1 -$5.42
Investments $61.42 $248.72 -$311.57
Total cash flows from investing -$0.67 $59.89 $247.62 -$316.99
Financing activities
Dividends paid
Sale and purchase of stock $461.04 $405.84 $398.02 $383
Net borrowings $322.87
Total cash flows from financing $394.5 $365.66 $392.24 $692.18
Effect of exchange rate $0.14 -$0.49 -$2.02 $0.36
Change in cash and equivalents -$200.78 -$88.68 $74.71 $215.06
Fundamentals
Market cap $6.99B
Enterprise value $6.75B
Shares outstanding 119.56M
Revenue $396.59M
EBITDA -$495.21M
EBIT -$496.91M
Net Income -$528.63M
Revenue Q/Q 545.89%
Revenue Y/Y 425.83%
P/E ratio -13.23
EV/Sales 17.02
EV/EBITDA -13.63
EV/EBIT -13.59
P/S ratio 17.63
P/B ratio 35.31
Book/Share 1.66
Cash/Share 2.95
EPS -$4.42
ROA -60.39%
ROE -178.54%
Debt/Equity 3.05
Net debt/EBITDA -0.49
Current ratio 3.10
Quick ratio 2.50